Abstract
Since 2000 we have introduced 141 Infliximab infusions to 23 children with severe inflammatory bowel disease. A total of seven severe adverse reactions occurred in 26% (6 of 23) of the children. Four reactions were acute (anaphylaxis n = 2; allergic reaction n = 2) and 3/4 of these children were younger than 10 years of age. Two children developed an abscess and one child had septicaemia and brain lesions related to progressive multifocal leucoencephalopathy.
Conclusion:
adverse reactions to Infliximab infusions are common. Young children seem to be prone to severe allergic reactions although they are on azathioprine and conventional glucocorticoid therapy.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adolescent
-
Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
-
Antibodies, Monoclonal / adverse effects*
-
Antibodies, Monoclonal / therapeutic use
-
Azathioprine / therapeutic use
-
Child
-
Child, Preschool
-
Drug Hypersensitivity / epidemiology*
-
Female
-
Gastrointestinal Agents / adverse effects*
-
Gastrointestinal Agents / therapeutic use
-
Glucocorticoids / therapeutic use
-
Humans
-
Immunosuppressive Agents / therapeutic use
-
Inflammatory Bowel Diseases / drug therapy*
-
Infliximab
-
Male
-
Mesalamine / therapeutic use
-
Retrospective Studies
Substances
-
Anti-Inflammatory Agents, Non-Steroidal
-
Antibodies, Monoclonal
-
Gastrointestinal Agents
-
Glucocorticoids
-
Immunosuppressive Agents
-
Mesalamine
-
Infliximab
-
Azathioprine